Key considerations as Congress works towards PAHPA reauthorization

This week, PhRMAsubmitted comments to the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) regarding the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization draft. In our comments, we expressed our strong opposition to policy proposals that would inhibit the biopharmaceutical industry partnering with the government to address pressing public health needs. With many PAHPA programs set to expire on September 30th and only a few legislative days left before the start of August work period, it is critical that lawmakers of both parties work together to ensure timely reauthorization of core programs authorized under PAHPA.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Research and Development Drug Cost Coronavirus Antimicrobial Resistance Source Type: news